Q linea

Q linea Liabilities

The The Liabilities of Q linea (QLINEA.ST) as of Nov 19, 2026 is 31.67 M SEK. In the previous year, The Liabilities was 175.45 M SEK — a change of -81.95% (lower).

Liabilities

31.67 MSEK

YoY

-81.95%

Last updated:

In 2025, Q linea's total liabilities amounted to 31.67 M SEK, a -81.95% difference from the 175.45 M SEK total liabilities in the previous year.

The Q linea Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
25.61 M SEK
Jan 1, 2019
33.46 M SEK
Jan 1, 2020
32.04 M SEK
Jan 1, 2021
35.85 M SEK
Jan 1, 2022
45.76 M SEK
Jan 1, 2023
42.34 M SEK
Jan 1, 2024
175.45 M SEK
Jan 1, 2025
31.67 M SEK
The Q linea Liabilities history
YEARLiabilitiesYoY
31.67 MSEK-81.95%
175.45 MSEK+314.37%
42.34 MSEK-7.47%
45.76 MSEK+27.65%
35.85 MSEK+11.89%
32.04 MSEK-4.26%
33.46 MSEK+30.66%
25.61 MSEK+51.67%
16.89 MSEK+100.84%
8.41 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Q linea's Liabilities

Q linea's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Q linea's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Q linea's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Q linea's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Q linea’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Q linea stock

The Liabilities of Q linea is 31.67 M SEK in 2025.

The Liabilities of Q linea changed from 175.45 M SEK to 31.67 M SEK, representing a -81.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Q linea since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Q linea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Q linea

All Key Metrics — Q linea